Open AccessWas it worth the weight? - Drug review on two new weight loss agents: lorcaserin (Belviq®) and phentermine/topiramate ER (QsymiaTM)
Author(s) -
Aaron W. Crawford,
Tiffany-Jade Kreys
Publication year - 2012
Publication title -
mental health clinician
Language(s) - English
Resource type - Journals
ISSN - 2168-9709
DOI - 10.9740/mhc.n129047
Subject(s) - topiramate , phentermine , weight loss , medicine , dosing , adverse effect , drug , rimonabant , anesthesia , pharmacology , obesity , psychiatry , epilepsy , agonist , receptor , cannabinoid receptor
The prevalence of obesity in the United States (U.S.) is currently at 34%. This article will review two of the newer weight loss agents: lorcaserin and phentermine/topiramate. Mechanism of action, dosing, adverse events, and drug interactions will be discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom